New Mechanism for Treatment of Schizophrenia


Hear details from the phase II trial of xanomeline-trospium and how it assists in the treatment of acute schizophrenia.

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on their additional data presentation from the ACNP.

To get a closer look at the Phase 2 EMERGENT-1 poster that was presented at ACNP, see here.

Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Recent Videos
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia
nicotine use
brain schizophrenia
exciting, brain
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
© 2024 MJH Life Sciences

All rights reserved.